“A 'True Industry Expert' is the phrase that I would use to best describe Jen. I have had the pleasure of working alongside Jen for the past 3 years, building on and improving daVIZta's Gross-to-Net automation software suite. Jen's numerous years of experience in the Pharmaceutical Gross-to-Net industry are evident in her daily interactions with her colleagues, clients, and mentees. I am continually impressed by Jen's ability to command a room, oftentimes responsible for influencing clients, including those who were initially on completely different pages, to realign their thinking on a given topic. She does it with ease. As a colleague, leader, and subject matter expert, Jen is a true asset to any company.”
About
Driven, strategic thinking executive with more than 26 years of expertise in Accounting…
Activity
-
We welcome Richard Moore, Jeff Blake, Nicholas Lynch, CFE, Walter Worsham and the entire Federal Compliance Solutions, an IntegriChain Company team…
We welcome Richard Moore, Jeff Blake, Nicholas Lynch, CFE, Walter Worsham and the entire Federal Compliance Solutions, an IntegriChain Company team…
Liked by Jennifer Sharpe, MBA
-
Excited to bring Federal Compliance Solutions, an IntegriChain Company into our family! Congratulations to Richard Moore, Nicholas Lynch, CFE, Jeff…
Excited to bring Federal Compliance Solutions, an IntegriChain Company into our family! Congratulations to Richard Moore, Nicholas Lynch, CFE, Jeff…
Liked by Jennifer Sharpe, MBA
-
Our own William Roth Roth weighs in on the state of the generics industry and the Medicare Drug Shortage Prevention and Mitigation Program proposed…
Our own William Roth Roth weighs in on the state of the generics industry and the Medicare Drug Shortage Prevention and Mitigation Program proposed…
Liked by Jennifer Sharpe, MBA
Experience & Education
-
IntegriChain
View Jennifer’s full experience
See their title, tenure and more.
or
Languages
-
Spanish
-
Recommendations received
5 people have recommended Jennifer
Join now to viewMore activity by Jennifer
-
IntegriChain and Blue Fin Group, an IntegriChain Company, is LIVE at the Asembia Specialty Pharmacy Summit! Visit booth 1414 and learn how we assist…
IntegriChain and Blue Fin Group, an IntegriChain Company, is LIVE at the Asembia Specialty Pharmacy Summit! Visit booth 1414 and learn how we assist…
Liked by Jennifer Sharpe, MBA
-
A huge thanks to everyone who joined us yesterday at the RAC Summit! We loved connecting with all of you. It was a fantastic day filled with…
A huge thanks to everyone who joined us yesterday at the RAC Summit! We loved connecting with all of you. It was a fantastic day filled with…
Liked by Jennifer Sharpe, MBA
-
Don't miss the RAC Summit tomorrow, March 12th, at the Hilton Garden Inn: https://lnkd.in/e_i6ziPM We're excited to be a sponsor and bring you…
Don't miss the RAC Summit tomorrow, March 12th, at the Hilton Garden Inn: https://lnkd.in/e_i6ziPM We're excited to be a sponsor and bring you…
Liked by Jennifer Sharpe, MBA
-
Learn strategic and tactical best practices for all channels and payer types. Register today for our Asset Valuation Throughout the Product Life…
Learn strategic and tactical best practices for all channels and payer types. Register today for our Asset Valuation Throughout the Product Life…
Liked by Jennifer Sharpe, MBA
-
If #pharma Gross-to-Net (GTN) makes your head spin, do 2 things: 1. Read the blog below from Jennifer Sharpe, MBA 2. Attend the FREE IntegriChain…
If #pharma Gross-to-Net (GTN) makes your head spin, do 2 things: 1. Read the blog below from Jennifer Sharpe, MBA 2. Attend the FREE IntegriChain…
Liked by Jennifer Sharpe, MBA
-
Step into the world of Expo '24! Our Pune office buzzed with excitement as employees explored different functional areas through engaging booths…
Step into the world of Expo '24! Our Pune office buzzed with excitement as employees explored different functional areas through engaging booths…
Liked by Jennifer Sharpe, MBA
-
Navigate the maze of pharma product, pricing, contracts, and data. In this blog, Jennifer Sharpe, MBA, explores critical considerations for accurate…
Navigate the maze of pharma product, pricing, contracts, and data. In this blog, Jennifer Sharpe, MBA, explores critical considerations for accurate…
Liked by Jennifer Sharpe, MBA
-
Today we’re excited to announce positive results from the Phase 3 studies of our investigational treatment for moderate-to-severe acute pain. Learn…
Today we’re excited to announce positive results from the Phase 3 studies of our investigational treatment for moderate-to-severe acute pain. Learn…
Liked by Jennifer Sharpe, MBA
-
Ninety-two percent of the units/prescriptions are generics, and 8% are brands. Of the 8% that are brands, roughly 80% of these are driven by the…
Ninety-two percent of the units/prescriptions are generics, and 8% are brands. Of the 8% that are brands, roughly 80% of these are driven by the…
Liked by Jennifer Sharpe, MBA
-
An insightful update about the notable changes in the pharma industry for January 2024, including the new Medicare Part D Agreement, the implications…
An insightful update about the notable changes in the pharma industry for January 2024, including the new Medicare Part D Agreement, the implications…
Liked by Jennifer Sharpe, MBA
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Jennifer Sharpe, MBA
2 others named Jennifer Sharpe, MBA are on LinkedIn
See others named Jennifer Sharpe, MBA